CSL Ltd. Chief Executive Officer Paul McKenzie is stepping down effective immediately, just months after the company scrapped a short-lived plan to spin off its Seqirus vaccine business. This sudden departure comes as the Australian biotechnology giant grapples with strategic direction following the aborted separation of its lucrative vaccine division. McKenzie's resignation leaves a leadership vacuum at a company facing intense competition in the global vaccine market and ongoing scrutiny over its corporate governance. The immediate succession process will now take center stage as CSL navigates this leadership transition amid questions about its future strategy for Seqirus. Market analysts suggest this move signals potential shifts in CSL's approach to its vaccine operations and broader portfolio management, though the company has not disclosed specific reasons for McKenzie's departure beyond the failed spinoff attempt. CSL's stock experienced modest volatility in response to the announcement, reflecting investor uncertainty about the implications for the company's valuation and growth prospects. The board is expected to move swiftly to appoint a new CEO who can provide stability and clarity on Seqirus's future, which remains a critical asset for CSL's revenue and international presence.